Drug
Imc I109v Single Ascending Dose
Imc I109v Single Ascending Dose: highest development phase Phase 1, developed by Immunocore. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Immunocore
Trials
| Drug | Phase | Indication |
|---|---|---|
| IMC-I109V Single Ascending Dose NCT05867056 | Phase 1 | Hepatitis B, Chronic |
Latest
No recent events.
Follow Imc I109v Single Ascending Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.